Skip to main content
Premium Trial:

Request an Annual Quote

Incyte Collaborates on Database with CVT

Premium

PALO ALTO, Calif.--CV Therapeutics and Incyte Pharmaceuticals have entered into a collaboration to develop a prototype gene expression database in the area of cardiovascular biology. The companies said the research program will address some major cardiovascular disease states, such as atherosclerosis and restenosis. Incyte will contribute its genomics capabilities, while CV will provide its molecular cardiology expertise.

Incyte will own the resulting data, and CV will receive a perpetual, nonexclusive license to use the data in its drug development efforts.

"The era of developing drugs by following the biological response of a single gene is drawing to a close," stated Richard Lawn, CV's vice-president of discovery research.

Filed under

The Scan

CDC Calls Delta "Variant of Concern"

CNN reports the US Centers for Disease Control and Prevention now considers the Delta variant of SARS-CoV-2 to be a "variant of concern."

From FDA to Venture Capital

Former FDA Commissioner Stephen Hahn is taking a position at a venture capital firm, leading some ethicists to raise eyebrows, according to the Washington Post.

Consent Questions

Nature News writes that there are questions whether informed consent was obtained for some submissions to a database of Y-chromosome profiles.

Cell Studies on Multimodal Single-Cell Analysis, Coronaviruses in Bats, Urban Microbiomes

In Cell this week: approach to analyze multimodal single-cell genomic data, analysis of bat coronaviruses, and more.